NCT00611468View on ClinicalTrials.gov

Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Metastatic Solid Tumor
Interventions
DRUG

Topotecan

All subjects receive treatment with intravenous topotecan and oral erlotinib.

DRUG

Erlotinib

All subjects receive treatment with intravenous topotecan and oral erlotinib.

Trial Locations (1)

38120

The West Clinic, Memphis

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Accelerated Community Oncology Research Network

OTHER